REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
28/01/2025
Voltar para busca
Dado oficial do USPTO
NUTRITION ADVANCING LIFE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
NUTRITION ADVANCING LIFE
ST13
US500000079256120Classe
5, 42
Pedido
79256120
Registro
5969827
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
28
Atualização mais recente
28/01/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
26/02/2019
Data de registro
28/01/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/01/2020
Última transação
28/01/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
82
Localização do titular
AU
Examinador
LAM, HAI-LY
Unidade examinadora
M30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Vernx Pty Ltd
Vernx Biotechnology Pty Ltd
Representantes
Michelle P. Ciotola Cantor Colburn LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and substances for the treatmentprevention and management of immune disorders and inflammatory diseases of the gastrointestinal systemgastro-intestinal diseases and intestinal diseases in babies and infants; gastro-intestinal treatment preparations; medicines for human use for the treatmentprevention and management of immune disorders and inflammatory diseases of the gastrointestinal systemgastro-intestinal diseases and intestinal diseases in babies and infants; medicines for intestinal disorders; pharmaceutical productsnamely pillscapsulestabletscapletsliquid dropssachets and beverages for the treatmentprevention and management of immune disorders and inflammatory diseases of the gastrointestinal systemgastro-intestinal diseases and intestinal diseases in babies and infants; chemical preparations for pharmaceutical purposes for the treatmentprevention and management of immune disorders and inflammatory diseases of the gastrointestinal systemgastro-intestinal diseases and intestinal diseases in babies and infants; chemicals for pharmaceutical use for the treatmentprevention and management of immune disorders and inflammatory diseases of the gastrointestinal systemgastro-intestinal diseases and intestinal diseases in babies and infants; diagnostic preparations for medical purposes; pharmaceutical preparationsherbal supplements and veterinary preparations all for the preventiontreatment and management of immune disorders and inflammatory diseases of the gastrointestinal system
Classe 42
Scientific and technological services and research and design relating theretonamely pharmaceutical research and new product developmentresearch and design thereto; scientific and technological research services in the pharmaceuticalbiotechnologybiochemistry and chemistry fields; scientific and medical research services; pharmaceutical research services; research relating to pharmaceuticals; research and development of pharmaceutical products; biotechnology research; biochemistry research and chemical research services; scientific research relating to biology and chemistry; scientific research in the field of pharmacy; scientific research into the development of new products; services for assessing the efficacy and safety of pharmaceuticalsnamely pharmaceutical product evaluation and testing and inspection of pharmaceuticals; preparation of scientific reports relating to scientific research; analytical laboratory servicesnamely chemical and medical laboratories; laboratory research and analysis in the pharmaceuticalbiotechnologybiochemistry and chemistry fields; development of products; development of new products; advisory services relating to scientific research; scientific consultancy and information services relating to the aforementioned services
Publicações
Histórico de despachos e eventos da marca no USPTO.
28 publicações encontradas
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
24/09/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
29/05/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/05/2020
FIMP
FINAL DISPOSITION PROCESSED
07/05/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/04/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
28/01/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/11/2019
PUBO
PUBLISHED FOR OPPOSITION
12/11/2019
GPNX
NOTIFICATION PROCESSED BY IB
09/11/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/10/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
23/10/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/10/2019
ALIE
ASSIGNED TO LIE
10/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/09/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/09/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
27/06/2019
RFNT
REFUSAL PROCESSED BY IB
22/06/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/06/2019
RFRR
REFUSAL PROCESSED BY MPU
01/06/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/05/2019
CNRT
NON-FINAL ACTION WRITTEN
13/05/2019
DOCK
ASSIGNED TO EXAMINER
07/05/2019
MAFR
APPLICATION FILING RECEIPT MAILED
16/04/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/04/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/04/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NUTRITION ADVANCING LIFE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.